{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:45:22Z","timestamp":1788475522451,"version":"build-2803163510"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Osimertinib is recommended for T790M mutation\u2010positive advanced non\u2010small cell lung cancer (NSCLC) resistant to first\u2010 and second\u2010generation epidermal growth factor receptor (EGFR)\u2010tyrosine kinase inhibitors (TKIs). Recently, some reports exist on the real\u2010world use of osimertinib; however, reports involving third\/later\u2010line use are few. Hence, this study was conducted to evaluate the efficacy and safety of osimertinib used in various treatment lines for T790M\u2010positive NSCLC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective, observational, multicenter study included T790M\u2010positive advanced\/recurrent NSCLC patients treated with osimertinib from May 2016 to March 2018. The clinical characteristics, efficacy, and adverse events were retrospectively investigated. The Kaplan\u2010Meier method was used to analyze progression\u2010free survival (PFS) and overall survival (OS). PFS\u2010associated clinical characteristics were evaluated using the Cox proportional hazards model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The objective response rate (ORR) and disease control rate (DCR) were 60.7% and 91.1%, respectively; the median PFS was 11.0 months. There were no significant differences in the median PFS for patients treated with osimertinib as second\u2010line and third\u2212\/later\u2010line (14.5 vs. 11.0\u2009months respectively, <jats:italic>P<\/jats:italic> =\u20090.327). Analysis using the Cox proportional hazards model for clinical features affecting PFS also revealed no significant factors. Adverse events of grade\u2009\u2265\u20093 were reported in 15 patients (26.8%); the most common were anemia (<jats:italic>n<\/jats:italic> =\u20093) and cutaneous toxicity (<jats:italic>n<\/jats:italic> =\u20093). Grade 4 neutropenia was observed in one patient; any\u2010grade pneumonitis was observed in six patients (10.7%), including one with grade 3 pneumonitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Osimertinib demonstrated efficacy even when administered as third\u2212\/later\u2010line treatment to NSCLC patients. Osimertinib\u2010related pneumonitis was observed more frequently than previously reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key points<\/jats:title><jats:sec><jats:title>Significant findings of the study<\/jats:title><jats:p>Osimertinib shows efficacy even as later\u2010line treatment in T790M mutation\u2010positive NSCLC patients previously treated with EGFR\u2010TKIs. However, the incidence of \u2265 grade 3 adverse events, especially pneumonitis, was higher than that previously reported by other studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>What this study adds<\/jats:title><jats:p>Osimertinib was approved for previously EGFR\u2010TKI\u2010treated EGFR T790M\u2010positive NSCLC. With the increasing frequency of its use as first\u2010line treatment, this study provides valuable evidence for the efficacy and safety of osimertinib for previously EGFR\u2010TKI\u2010treated NSCLC.<\/jats:p><\/jats:sec><\/jats:sec>","DOI":"10.1111\/1759-7714.13378","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T16:26:36Z","timestamp":1583339196000},"page":"935-942","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Osimertinib, a third\u2010generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real\u2010world efficacy and safety in advanced\/recurrent non\u2010small cell lung carcinoma"],"prefix":"10.1111","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8957-4814","authenticated-orcid":false,"given":"Takayuki","family":"Kishikawa","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine Tochigi Cancer Center  Utsunomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kasai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Tochigi Cancer Center  Utsunomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Okada","sequence":"additional","affiliation":[{"name":"Pulmonary Division, Department Internal Medicine Saiseikai Utsunomiya Hospital  Utsunomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakachi","sequence":"additional","affiliation":[{"name":"Pulmonary Division, Department Internal Medicine Saiseikai Utsunomiya Hospital  Utsunomiya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayo","family":"Soda","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology Dokkyo Medical University School of Medicine  Shimotuga\u2010Gun Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine and Clinical Immunology Dokkyo Medical University School of Medicine  Shimotuga\u2010Gun Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Takigami","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine Jichi Medical University Hospital  Shimotsuke\u2010City Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Sata","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine Jichi Medical University Hospital  Shimotsuke\u2010City Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0062"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909530"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70184-X"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.10.002"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.01.013"},{"issue":"5","key":"e_1_2_7_11_1","first-page":"411","article-title":"EGFR\u2010TKI resistance in NSCLC patients: Mechanisms and strategies","volume":"4","author":"Lin Y","year":"2014","journal-title":"Am J Cancer Res"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.02.010"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00008413"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30508-3"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.3223"},{"key":"e_1_2_7_21_1","first-page":"405","article-title":"High prevalence of drug\u2010induced pneumonia in Japan","volume":"50","author":"Azuma A","year":"2007","journal-title":"JMAJ"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyt049"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ca12e0"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw647"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0389-9"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13039"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221575"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S221434"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1759-7714.13378","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13378","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.13378","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.13378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:07:56Z","timestamp":1694045276000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.13378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1111\/1759-7714.13378"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.13378","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"2020-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}